DeepMed Research

WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2005-03-04

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 5

Registration Number: NCT00104806

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer

Phase 1

Completed

Conditions: Fatigue
Breast Cancer

Interventions: Dietary Supplement: Placebo & Vitamin E
Dietary Supplement: CoQ10 & Vitamin E

First Posted Date: 2004-11-09

Last Posted Date: 2021-09-29

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 236

Registration Number: NCT00096356

Locations: 🇺🇸
MBCCOP - JHS Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
CCOP - Beaumont, Royal Oak, Michigan, United States

and more 28 locations

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-09-03

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 136

Registration Number: NCT00002942

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-11

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 25

Registration Number: NCT00002865

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix

Phase 1

Terminated

Conditions: Cervical Cancer

First Posted Date: 2004-06-11

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 15

Registration Number: NCT00084890

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-05-19

Last Posted Date: 2017-01-19

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT00082940

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
St. Joseph Hospital Regional Cancer Center - Orange, Orange, California, United States
🇺🇸
Cancer Care Specialists, Houma, Louisiana, United States

and more 8 locations

Gemcitabine in Treating Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-04-13

Last Posted Date: 2021-09-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 15

Registration Number: NCT00007943

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-04-12

Last Posted Date: 2017-01-19

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT00003840

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-03-09

Last Posted Date: 2021-09-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 18

Registration Number: NCT00079092

Locations: 🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸
CCOP - Greenville, Greenville, South Carolina, United States

and more 2 locations

Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2003-11-26

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 40

Registration Number: NCT00003202

Locations: 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy